Compare Ascendis Pharma A/S (ASND) vs Quanta Services Inc (PWR) Price & Performance

Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.

The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.

Quanta Services (PWR) trades at $658.56, down 1.44% with a bearish technical signal despite strong fundamental performance. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Revenue growth has been robust, increasing from $17.1B in 2022 to $28.5B in 2025, though profit margins remain modest at 3.67%. Analyst sentiment remains overwhelmingly positive with 27 buy ratings and a consensus price target of $836.80, representing 27% upside potential.

PWR presents a compelling growth story driven by infrastructure spending and AI-related opportunities, with management projecting technology revenues to rise over 110% by 2030. However, the stock trades at premium valuations (P/E 90.34) and faces execution risks from aggressive capital expenditure plans. The bearish technical setup suggests near-term pressure, but strong institutional support and massive infrastructure backlog provide long-term catalysts.